Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
The Motley Fool
by newsfeedback@fool.com (Motley Fool YouTube)March 6, 2026
Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility.
Verticals
financeinvesting
Originally published on The Motley Fool on 3/6/2026